Cargando…
Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer
PURPOSE: Cisplatin-associated arterial and venous thromboembolic events (TEEs) are becoming an increasing concern. In patients with small-cell lung cancer (SCLC) who are treated using cisplatin-based chemotherapy, we assume that the overall risk of TEEs is high. However, cisplatin-associated vascula...
Autores principales: | Lee, Yun-Gyoo, Lee, Eunyoung, Kim, Inho, Lee, Keun-Wook, Kim, Tae Min, Lee, Se-Hoon, Kim, Dong-Wan, Heo, Dae Seog |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4614217/ https://www.ncbi.nlm.nih.gov/pubmed/25672586 http://dx.doi.org/10.4143/crt.2014.045 |
Ejemplares similares
-
A Phase II Study of Genexol‐PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Keam, Bhumsuk, et al.
Publicado: (2019) -
Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
por: Kim, Miso, et al.
Publicado: (2017) -
Influence of Comorbidities on the Efficacy of Radiotherapy with or without Chemotherapy in Elderly Stage III Non-small Cell Lung Cancer Patients
por: Lee, Joo Ho, et al.
Publicado: (2012) -
Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer
por: Kim, Dong-Wan, et al.
Publicado: (2019) -
Phase II Study of Low-dose Paclitaxel and Cisplatin as a Second-line Therapy after 5-Fluorouracil/Platinum Chemotherapy in Gastric Cancer
por: Lee, Keun-Wook, et al.
Publicado: (2007)